Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

Umberto Restelli1 Center for Health Economics, Social and Health Care Management, LIUC – Università Cattaneo, Castellanza, Italy;2 School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaCorrespondence[email protected]

Massimiliano Fabbiani3 Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart

Simona Di Giambenedetto3 Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart

Carmela Nappi4 Health Economics, Bristol Myers Squibb S.r.l., Rome, Italy

Davide Croce1 Center for Health Economics, Social and Health Care Management, LIUC – Università Cattaneo, Castellanza, Italy;2 School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (3)

Kevin M Gibas, Sean G Kelly, Jose R Arribas, Pedro Cahn, Chloe Orkin, Eric S Daar, Paul E Sax & Babafemi O Taiwo. (2022) Two-drug regimens for HIV treatment. The Lancet HIV 9:12, pages e868-e883.
Crossref

Massimiliano Fabbiani, Roberta Gagliardini, Nicoletta Ciccarelli, Eugenia Quiros Roldan, Alessandra Latini, Gabriella d’Ettorre, Andrea Antinori, Antonella Castagna, Giancarlo Orofino, Daniela Francisci, Pierangelo Chinello, Giordano Madeddu, Pierfrancesco Grima, Stefano Rusconi, Barbara Del Pin, Francesca Lombardi, Alessandro D’Avino, Emanuele Focà, Manuela Colafigli, Roberto Cauda, Simona Di Giambenedetto, Andrea De Luca, R Cauda, S Di Giambenedetto, M Fabbiani, A Mondi, N Ciccarelli, A Borghetti, E Baldonero, S Belmonti, A D’Avino, R Gagliardini, S Lamonica, F Lombardi, L Sidella, E Tamburrini, E Visconti, A De Luca, A Giacometti, F Barchiesi, P Castelli, O Cirioni, S Mazzocato, M Di Pietro, P Blanc, A Degli Esposti, B Del Pin, E Mariabelli, S Marini, A Poggi, E Quiros Roldan, E Focà, S Amadasi, A Apostoli, L Biasi, A Bonito, N Brianese, S Compostella, A Ferraresi, D Motta, M T Mughini, B M Celesia, M Gussio, S Sofia, P Grima, M Tana, P Tundo, C Viscoli, L De Hoffer, A Di Biagio, S Grignolo, A Parisini, E Schenone, L Taramasso, P E Manconi, A Boccone, F Ortu, P Piano, L Serusi, M Puoti, M C Moioli, R Rossotti, G Travi, F Ventura, M Galli, S Rusconi, S Di Nardo Stuppino, V Di Cristo, A Giacomelli, V Vimercati, P Viale, A Gori, G Rizzardini, A Capetti, L Carenzi, F Mazza, P Meraviglia, S Rosa, P Zucchi, M Mineo, A Latini, M Colafigli, M Giuliani, A Pacifici, F Pimpinelli, F Solivetti, F Stivali, A Antinori, F Angelici, R Bellagamba, D Delle Rose, R Fezza, R Libertone, S Mosti, P Narciso, E Nicastri, S Ottou, C Tomassi, C Vlassi, M Zaccarelli, F Zoppè, V Vullo, G D’Ettorre, F Altavilla, G Ceccarelli, A Fantauzzi, S Gebremeskel, S Lo Menzo, I Mezzaroma, F Tierno, N Petrosillo, P Chinello, E Boumis, S Cicalini, E Grilli, M Musso, C Stella, M S Mura, G Madeddu, P Bagella, M Mannazzu, V Soddu, P Caramello, G Orofino, C Carcieri, S Carosella, M Farenga, P G Scotton, M C Rossi, E Concia, F Corsini, C Gricolo, M Lanzafame, E Lattuada, S Leonardi, F Rigo, A Lazzarin, A Castagna, A Bigoloni, E Carini, S Nozza, V Spagnuolo, D Francisci, B Belfiori, L Malincarne, E Schiaroli, C Sfara, A Tosti, D Sacchini, A Ruggieri & C Valdatta. (2018) Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. Journal of Antimicrobial Chemotherapy 73:7, pages 1955-1964.
Crossref

. (2017) Atazanavir-based dual therapy decreases costs in HIV patients. PharmacoEconomics & Outcomes News 789:1, pages 11-11.
Crossref

Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

Articles from other publishers (3)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Update of the budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

Citations (3)

Articles from other publishers (3)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date